TW202116305A - 用於治療狗之慢性腎臟病之替米沙坦（ｔｅｌｍｉｓａｒｔａｎ） - Google Patents

用於治療狗之慢性腎臟病之替米沙坦（ｔｅｌｍｉｓａｒｔａｎ） Download PDF

Info

Publication number
TW202116305A
TW202116305A TW109114512A TW109114512A TW202116305A TW 202116305 A TW202116305 A TW 202116305A TW 109114512 A TW109114512 A TW 109114512A TW 109114512 A TW109114512 A TW 109114512A TW 202116305 A TW202116305 A TW 202116305A
Authority
TW
Taiwan
Prior art keywords
telmisartan
upc
treatment
dogs
time period
Prior art date
Application number
TW109114512A
Other languages
English (en)
Chinese (zh)
Inventor
安 米雪兒 特拉斯
史考特 艾倫 布朗
亞曼達 艾瑞克森 科爾曼
凱特 伊麗莎白 克里維
比昂卡 娜塔莉亞 費雷拉 得 莫拉 盧倫科
Original Assignee
德商百靈佳殷格翰維美迪加股份有限公司
美國喬治亞大學研究基金會公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商百靈佳殷格翰維美迪加股份有限公司, 美國喬治亞大學研究基金會公司 filed Critical 德商百靈佳殷格翰維美迪加股份有限公司
Publication of TW202116305A publication Critical patent/TW202116305A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109114512A 2019-07-09 2020-04-30 用於治療狗之慢性腎臟病之替米沙坦（ｔｅｌｍｉｓａｒｔａｎ） TW202116305A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871752P 2019-07-09 2019-07-09
US62/871,752 2019-07-09

Publications (1)

Publication Number Publication Date
TW202116305A true TW202116305A (zh) 2021-05-01

Family

ID=70775531

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109114512A TW202116305A (zh) 2019-07-09 2020-04-30 用於治療狗之慢性腎臟病之替米沙坦（ｔｅｌｍｉｓａｒｔａｎ）

Country Status (10)

Country Link
US (1) US20220218671A1 (https=)
EP (1) EP3996705A1 (https=)
JP (2) JP2022540074A (https=)
KR (1) KR20220054291A (https=)
CN (1) CN114450004A (https=)
BR (1) BR112022000315A2 (https=)
CA (1) CA3142876A1 (https=)
MX (1) MX2022000429A (https=)
TW (1) TW202116305A (https=)
WO (1) WO2021006941A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220054292A (ko) 2019-07-09 2022-05-02 베링거잉겔하임베트메디카게엠베하 개의 고혈압 치료를 위한 텔미사르탄

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3648761T (pt) 2017-07-07 2024-06-05 Boehringer Ingelheim Vetmedica Gmbh Telmisartan para a profilaxia ou tratamento de hipertensão em gatos

Also Published As

Publication number Publication date
US20220218671A1 (en) 2022-07-14
EP3996705A1 (en) 2022-05-18
KR20220054291A (ko) 2022-05-02
JP2022540074A (ja) 2022-09-14
CA3142876A1 (en) 2021-01-14
BR112022000315A2 (pt) 2022-02-22
CN114450004A (zh) 2022-05-06
AU2020311280A1 (en) 2022-02-24
JP2025120167A (ja) 2025-08-15
WO2021006941A1 (en) 2021-01-14
MX2022000429A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
US20080206237A1 (en) Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
JP2025115405A (ja) イヌの高血圧の治療のためのテルミサルタン
JP2025120167A (ja) イヌの慢性腎臓病の治療のためのテルミサルタン
US20250195525A1 (en) Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats
RU2832966C2 (ru) Телмисартан для лечения хронической болезни почек у собак
EA026713B1 (ru) Твердая пероральная лекарственная форма для лечения дефицита железа или анемии и ее применение
AU2020311280B2 (en) Telmisartan for the treatment of chronic kidney disease in dogs
RU2830555C2 (ru) Телмисартан для лечения гипертонии у собак
AU2020310059B2 (en) Telmisartan for the treatment of hypertension in dogs
Zheng et al. Isoliensinine Ameliorates Postoperative Neurocognitive Disorder in Aged Mice by Restoring Hippocampal IGF-1 Receptor Signaling and Suppressing Oxidative Stress and Neuroinflammation
AU2007304216B9 (en) Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
JP2010513219A (ja) 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療